Clitocine
Modify Date: 2024-01-20 18:40:04
Clitocine structure
|
Common Name | Clitocine | ||
|---|---|---|---|---|
| CAS Number | 105798-74-1 | Molecular Weight | 287.22900 | |
| Density | 1.82g/cm3 | Boiling Point | 702.4ºC at 760 mmHg | |
| Molecular Formula | C9H13N5O6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 378.6ºC | |
Use of ClitocineClitocine, an adenosine nucleoside analog, is a potent and efficacious readthrough agent. Clitocine can induce the production of p53 protein in cells harboring p53 nonsense-mutated alleles. Clitocine can induce apoptosis in multidrug-resistant human cancer cells by targeting Mcl-1. Anticancer activity[1][2]. |
| Name | N-(6-Amino-5-nitro-4-pyrimidinyl)-β-D-ribofuranosylamine |
|---|---|
| Synonym | More Synonyms |
| Description | Clitocine, an adenosine nucleoside analog, is a potent and efficacious readthrough agent. Clitocine can induce the production of p53 protein in cells harboring p53 nonsense-mutated alleles. Clitocine can induce apoptosis in multidrug-resistant human cancer cells by targeting Mcl-1. Anticancer activity[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Clitocine (0-0.8μM; 24 hours) enhances TRAIL-lethality in in LS411N and SW620 cells. Clitocine (0.2μM; 36 hours) significantly potentiates TRAIL-mediated apoptosis[2]. |
| In Vivo | Citocine (0.3-3 mg/kg; s.c.; five times per week)-induced p53 inhibits CAOV-33p53-UAA136 tumor growth in a xenograft model[1]. Animal Model: nu/nu mice (CAOV-3p53-UAA136 xenograft tumors)[1] Dosage: 0.3, 3 mg/kg (or 20 mg/kg once per week) Administration: S.c.; five times per week Result: CAOV-33p53-UAA136 tumor growth was inhibited. |
| References |
| Density | 1.82g/cm3 |
|---|---|
| Boiling Point | 702.4ºC at 760 mmHg |
| Molecular Formula | C9H13N5O6 |
| Molecular Weight | 287.22900 |
| Flash Point | 378.6ºC |
| Exact Mass | 287.08700 |
| PSA | 179.57000 |
| Vapour Pressure | 1.04E-20mmHg at 25°C |
| Index of Refraction | 1.771 |
|
~%
Clitocine CAS#:105798-74-1 |
| Literature: Moss, Randall J.; Petrie, Charles R.; Meyer, Rich B.; Nord, L. Dee; Willis, Randall C.; et al. Journal of Medicinal Chemistry, 1988 , vol. 31, # 4 p. 786 - 790 |
|
~%
Clitocine CAS#:105798-74-1 |
| Literature: Choi, Hyeong-Wook; Choi, Bo Seung; Chang, Jay Hyok; Lee, Kyu Woong; Nam, Do Hyun; Kim, Young Keun; Lee, Jae Hoon; Heo, Taeho; Shin, Hyunik; Kim, No-Soo Synlett, 2005 , # 12 art. no. U12805ST, p. 1942 - 1944 |
|
~%
Clitocine CAS#:105798-74-1 |
| Literature: Kamikawa, Tadao; Fujie, Satoru; Yamagiwa, Yoshiro; Kim, Mujo; Kawaguchi, Hitoshi Journal of the Chemical Society, Chemical Communications, 1988 , # 3 p. 195 - 196 |
![6-amino-5-nitro-4-[(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)amino]pyrimidine structure](https://www.chemsrc.com/caspic/230/112220-31-2.png)
![(2-amino-7,7-dimethyl-3,6,8-trioxabicyclo[3.3.0]oct-4-yl)methanol; 4-methylbenzenesulfonic acid structure](https://www.chemsrc.com/caspic/053/51172-55-5.png)
| 6-amino-5-nitro-2-trifluoromethyl-3H-pyrimidin-4-one |
| 5-Nitro-6-aminouracil |
| 4-AMINO-2,6-DIHYDROXY-5-NITROPYRIMIDINE |
| 6-Amino-5-nitro-1H-pyrimidin-2,4-dion |
| 6-amino-4-hydroxy-5-nitro-2-trifluoromethylpyrimidine |
| 5-Nitro-6-amino-4-hydroxy-2-trifluormethyl-pyrimidin |
| 6-Amino-5-nitro-uracil |
| 6-amino-5-nitropyrimidine-2,4-diol |
| Clitocine |